鐳-223注射治療三次以上改善轉移性去勢抗性攝護腺癌病人之生存率

吳芃諺、洪晟鈞、裘坤元、盧嘉文、李建儀、王賢翔、楊晨洸、陳卷書、陳正哲、王樹吉、林嘉彥、張瓈文、程千里

台中榮民總醫院外科部泌尿科

Radium-223 Injection for More Then 3 Courses Improves Survival in Patients with Metastatic Castration-Resistant Prostate Cancer

Peng-Yen Wu, Sheng-Chun Hung, Kun-Yuan Chiu, Kevin Lu, Jian-Ri Li, Shian-Shiang Wang, Cheng-Kuang Yang, Chuan-Shu Chen, Cheng-Che Chen, Shu-Chi Wang, Chia-Yen Lin, Li-Wen Chang, Chen-Li Cheng

Division of Urology, Department of Surgery, Taichung Veterans General Hospital; Department of Urology

Purpose:

In previous studies, Radium-223 improved overall survival and quality of life in patients who have metastatic castration–resistant prostate cancer (mCRPC) with bone metastasis. The purpose of this study is to assess how numbers of Radium-223 injection impact clinical outcomes in patients with mCRPC.

Materials and Methods:

The charts of patients with mCRPC who received treatment with Radium-223, were retrospectively reviewed. The overall survival from treatment with Radium-223 were analyzed.

Results:

From October, 2016 to January, 2021, forty-two patients with mCRPC received treatment with Radium-223 in Taichung Veterans General Hospital. The average age of these patients was 70.63 years old. Among these 42 patients, five patients received 1 course of Radium-223 injection. Seven received 2, seven received 3, six received 4, four received 5, and 13 patients received 6 courses of Radium-223 injection. There was significant difference between median overall survival in patients who received ≤ 2 coursed of Radium-223 injection (n = 12) and those who received ≥ 3 courses of Radium-223 injection (n = 30) (2.18 months vs. 12.04 months, p < 0.001).

Conclusions:

In this study, Radium-223 prolonged overall survival significantly when patients with mCRPC receive ≥ 3 courses of Radium-223 injection.